Short Interest in Co-Diagnostics, Inc. (NASDAQ:CODX) Drops By 16.7%

Posted by Linda Flegge on Mar 18th, 2025

Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 193,700 shares, a decrease of 16.7% from the February 13th total of 232,600 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 207,200 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CODX. Geode Capital Management LLC lifted its holdings in Co-Diagnostics by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 345,511 shares of the company’s stock worth $259,000 after buying an additional 24,236 shares in the last quarter. Thompson Davis & CO. Inc. boosted its holdings in Co-Diagnostics by 37.8% in the fourth quarter. Thompson Davis & CO. Inc. now owns 57,200 shares of the company’s stock valued at $43,000 after acquiring an additional 15,700 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Co-Diagnostics in the third quarter worth about $55,000. 14.99% of the stock is currently owned by institutional investors and hedge funds.

Co-Diagnostics Price Performance

Co-Diagnostics stock traded up $0.00 during trading hours on Tuesday, hitting $0.45. The company had a trading volume of 53,462 shares, compared to its average volume of 173,021. Co-Diagnostics has a fifty-two week low of $0.45 and a fifty-two week high of $2.23. The firm’s fifty day moving average is $0.67 and its 200-day moving average is $0.94. The firm has a market capitalization of $14.46 million, a P/E ratio of -0.33 and a beta of 1.29.

Co-Diagnostics Company Profile

(Get Free Report)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.